$MEDP · Medpace Holdings, Inc.
Medpace Holdings CEO and 10% owner August J. Troendle reported the sale of 70,901 shares across two transactions on the open market, generating $44,428,151 in proceeds at prices between $623.29 and $628.11 per share. No 10b5-1 trading plan was indicated. Post-transaction, Troendle holds 433,372 shares.
- CEO August Troendle sold 70,901 shares for $44,428,151 total across two transactions.
- Sale prices ranged from $623.29 to $628.11 per share; no 10b5-1 plan was indicated.
- Troendle remains President, CEO, and 10% owner with 433,372 shares held post-transaction.
- The $44.4M disposition represents a significant cash-out by the company's top insider.
Stock was down 2.07% in the regular session to $617.15. The $44.4M CEO sale, executed without a 10b5-1 plan, may add pressure in after-hours trading given the size relative to typical insider dispositions.
A $44.4M unplanned CEO stock sale at a $17.2B market cap company raises questions about insider conviction at current valuation levels.
Medpace is a clinical CRO; insider selling at this scale by a founder-CEO may draw comparisons to peers like IQV and ICLR where insider activity is closely watched.
No 10b5-1 trading plan was used, meaning the CEO exercised discretion on timing — a potential signal of perceived near-term valuation risk.
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.